• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Foghorn Therapeutics Inc. - Common Stock (NQ:FHTX)

    4.360 +0.360 (+9.00%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Foghorn Therapeutics Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
     
    Via Benzinga
    ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
     
    Via Benzinga
    Foghorn Therapeutics: Q4 Earnings Insights
     
    Via Benzinga
    FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q2 2024
    FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Misses Revenue for Q1 2024
    FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
    Company presentation and fireside chat on April 11th at 11:45 a.m. ET 
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023
    FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
     
    Via Benzinga
    Why Foghorn Therapeutics (FHTX) Stock Is Exploding Higher
    Foghorn Therapeutics shares are trading higher by 44.8% Thursday. The company announced that Eli Lilly has chosen FHD-909 for clinical development. 
    Via Benzinga
    Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces CFO Departure
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.